國家衛生研究院 NHRI:Item 3990099045/14705

NHRI > National Institute of Infectious Diseases and Vaccinology > Others > Periodical Articles > Item 3990099045/14705

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14705

Title:	Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV
Authors:	Liu, WD;Pang, MW;Wang, JT;Sun, HY;Huang, YS;Lin, KY;Wu, UI;Li, GC;Liu, WC;Su, YC;He, PC;Lin, CY;Yeh, CY;Cheng, YC;Yao, Y;Chen, YT;Wu, PY;Chen, LY;Luo, YZ;Chang, HY;Sheng, WH;Hsieh, SM;Chang, SY;Hung, CC;Chang, SC
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	BACKGROUND: A community COVID-19 outbreak caused by the B.1.1.7 SARS-CoV-2 variant occurred in Taiwan in May 2021. High-risk populations such as people living with HIV (PLWH) were recommended to receive two doses of COVID-19 vaccines. While SARS-CoV-2 vaccines have demonstrated promising results in general population, real-world information on the serological responses remains limited among PLWH. METHODS: PLWH receiving the first dose of SARS-CoV-2 vaccine from 2020 to 2021 were enrolled. Determinations of anti-SARS-CoV-2 spike IgG titers were performed every one to three months, the third dose of the SARS-CoV-2 vaccine or confirmed SARS-CoV-2 infection. All serum samples were tested for anti-nucleocapsid antibody and those tested positive were excluded from analysis. RESULTS: A total of 1189 PLWH were enrolled: 829 (69.7%) receiving two doses of the AZD1222 vaccine, 232 (19.5%) of the mRNA-1273 vaccine, and 128 (10.8%) of the BNT162b2 vaccine. At all time-points, PLWH receiving two doses of mRNA vaccines had consistently higher antibody levels than those receiving the AZD1222 vaccine (p <0.001 for all time-point comparisons). Factors associated with failure to achieve an anti-spike IgG titer >141 BAU/mL within 12 weeks, included type 2 diabetes mellitus (DM) (adjusted odds ratio [aOR], 2.24; 95% CI, 1.25-4), a CD4 T cell count <200 cells/mm(3) upon receipt of the first dose of vaccination (aOR, 3.43; 95% CI, 1.31-9) and two homologous AZD1222 vaccinations (aOR, 16.85; 95%CI, 10.13-28). For those receiving two doses of mRNA vaccines, factors associated with failure to achieve an anti-spike IgG titer >899 BAU/mL within 12 weeks were a CD4 T cell count <200 cells/mm(3) on first-dose vaccination (aOR, 3.95; 95% CI, 1.08-14.42) and dual BNT162b2 vaccination (aOR, 4.21; 95% CI, 2.57-6.89). CONCLUSIONS: Two doses of homologous mRNA vaccination achieved significantly higher serological responses than vaccination with AZD1222 among PLWH. Those with CD4 T cell counts <200 cells/mm(3) and DM had consistently lower serological responses.
Date:	2022-12
Relation:	Journal of Virus Eradication. 2022 Dec;8(4):Article number 100308.
Link to:	http://dx.doi.org/10.1016/j.jve.2022.100308
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2055-6640&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000906235500001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85144431638
Appears in Collections:	[Others] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB36531082.pdf		3226Kb	Adobe PDF	253	View/Open

Loading...